KSI-101 Updated Nov 13
The December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.
- Phase 1b APEX data showed strong results: meaningful vision gains as early as week 4, over 90% of patients achieving absence of macular edema, and more than half of patients in top dose levels gaining 15+ letters (3 lines) on the eye chart after a single dose (source: Kodiak press release, September 2025)
- The company's platform and retinal disease expertise were validated by the September 2026 DAYBREAK Phase 3 success for Zenkuda and KSI-501, which de-risks the broader pipeline including KSI-101 (source: Kodiak 8-K filed November 12, 2026)
- Baker Bros. Advisors, a 10% owner and director, made large open-market purchases of roughly $24 million in early November 2026 at ~$98.51/share, signaling insider confidence ahead of the December readout
- Cash burn is severe: Q3 2026 net loss was $66.2 million, and cash dropped to $88.7 million at quarter-end (plus $69 million raised post-quarter via ATM). Stockholders' equity was only $12.6 million, raising going-concern risk if additional financing is not secured (source: Kodiak 10-Q filed November 12, 2026, and 8-K analysis)
- The stock already trades at a ~$6.8 billion market cap after the 178% DAYBREAK surge, embedding optimistic assumptions. A Seeking Alpha analyst (November 13, 2026) argues the valuation already prices in Zenkuda success and that more financing is likely (source: Seeking Alpha, November 13, 2026)
- Competition is emerging: Genentech/Roche is developing vamikibart for uveitic macular edema, with positive Phase III MEERKAT and SANDCAT data presented in October 2026 (source: Genentech press release via marketscreener, October 2026)